Past, Current, and Future of Immunotherapies for Prostate Cancer
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate canc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00884/full |
| _version_ | 1828889049590398976 |
|---|---|
| author | Adeline N. Boettcher Ahmed Usman Alicia Morgans David J. VanderWeele Jeffrey Sosman Jennifer D. Wu Jennifer D. Wu |
| author_facet | Adeline N. Boettcher Ahmed Usman Alicia Morgans David J. VanderWeele Jeffrey Sosman Jennifer D. Wu Jennifer D. Wu |
| author_sort | Adeline N. Boettcher |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has presented substantial benefits for many types of cancer, but only a marginal benefit for mCRPC, at least in part, due to the immunosuppressive tumor microenvironment (TME). Current clinical trials are investigating monotherapies or combination therapies involving adoptive cellular therapy, viral, DNA vaccines, oncolytic viruses, and immune checkpoint inhibitors (ICI). Immunotherapies are also being combined with chemotherapy, radiation, and AST. Additionally, preclinical investigations show promise with the recent description of alternative ways to circumvent the immunosuppressive nature of the prostate tumor microenvironment, including harnessing the immune stimulatory NKG2D pathway, inhibiting myeloid derived suppressor cells, and utilizing immunomodulatory oncolytic viruses. Herein we provide an overview of recent preclinical and clinical developments in cancer immunotherapies and discuss the perspectives for future immunotherapies in PCa. |
| first_indexed | 2024-12-13T12:33:56Z |
| format | Article |
| id | doaj.art-4e772e4f2d4f4145bd18b90287ba11c8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T12:33:56Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4e772e4f2d4f4145bd18b90287ba11c82022-12-21T23:45:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00884480845Past, Current, and Future of Immunotherapies for Prostate CancerAdeline N. Boettcher0Ahmed Usman1Alicia Morgans2David J. VanderWeele3Jeffrey Sosman4Jennifer D. Wu5Jennifer D. Wu6Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesProstate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has presented substantial benefits for many types of cancer, but only a marginal benefit for mCRPC, at least in part, due to the immunosuppressive tumor microenvironment (TME). Current clinical trials are investigating monotherapies or combination therapies involving adoptive cellular therapy, viral, DNA vaccines, oncolytic viruses, and immune checkpoint inhibitors (ICI). Immunotherapies are also being combined with chemotherapy, radiation, and AST. Additionally, preclinical investigations show promise with the recent description of alternative ways to circumvent the immunosuppressive nature of the prostate tumor microenvironment, including harnessing the immune stimulatory NKG2D pathway, inhibiting myeloid derived suppressor cells, and utilizing immunomodulatory oncolytic viruses. Herein we provide an overview of recent preclinical and clinical developments in cancer immunotherapies and discuss the perspectives for future immunotherapies in PCa.https://www.frontiersin.org/article/10.3389/fonc.2019.00884/fullprostate cancermetastatic-castration resistant prostate cancerimmunotherapycombination therapyimmune checkpoint inhibitor |
| spellingShingle | Adeline N. Boettcher Ahmed Usman Alicia Morgans David J. VanderWeele Jeffrey Sosman Jennifer D. Wu Jennifer D. Wu Past, Current, and Future of Immunotherapies for Prostate Cancer Frontiers in Oncology prostate cancer metastatic-castration resistant prostate cancer immunotherapy combination therapy immune checkpoint inhibitor |
| title | Past, Current, and Future of Immunotherapies for Prostate Cancer |
| title_full | Past, Current, and Future of Immunotherapies for Prostate Cancer |
| title_fullStr | Past, Current, and Future of Immunotherapies for Prostate Cancer |
| title_full_unstemmed | Past, Current, and Future of Immunotherapies for Prostate Cancer |
| title_short | Past, Current, and Future of Immunotherapies for Prostate Cancer |
| title_sort | past current and future of immunotherapies for prostate cancer |
| topic | prostate cancer metastatic-castration resistant prostate cancer immunotherapy combination therapy immune checkpoint inhibitor |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00884/full |
| work_keys_str_mv | AT adelinenboettcher pastcurrentandfutureofimmunotherapiesforprostatecancer AT ahmedusman pastcurrentandfutureofimmunotherapiesforprostatecancer AT aliciamorgans pastcurrentandfutureofimmunotherapiesforprostatecancer AT davidjvanderweele pastcurrentandfutureofimmunotherapiesforprostatecancer AT jeffreysosman pastcurrentandfutureofimmunotherapiesforprostatecancer AT jenniferdwu pastcurrentandfutureofimmunotherapiesforprostatecancer AT jenniferdwu pastcurrentandfutureofimmunotherapiesforprostatecancer |